Related Experiment Video

Updated: Apr 3, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

G O'Callaghan1,2, A Houston1,3

  • 1Department of Medicine, University College Cork, Cork, Ireland.

British Journal of Pharmacology
|September 18, 2015
PubMed

Insights

Elevated cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) fuel cancer. Targeting E-type prostanoid (EP) receptors offers a safer therapeutic strategy for cancer and metastasis, avoiding COX-2 inhibitor toxicities.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Elevated cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) are implicated in numerous cancers, driving tumor development and progression.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors show potential in cancer prevention and treatment, but toxicities limit their use.
  • Prostaglandin E2 exerts its biological effects via four E-type prostanoid (EP) receptors: EP1, EP2, EP3, and EP4.

Purpose of the Study:

  • To review the role of PGE2 and its individual EP receptors in neoplastic disease.
  • To explore the potential of EP receptors as therapeutic targets for cancer and metastatic disease.
  • To highlight the need for strategies to reduce COX-2 activity without adverse side effects.

Main Methods:

  • Literature review focusing on PGE2 and EP receptor signaling pathways in cancer.
  • Analysis of existing epidemiological, clinical, and preclinical data.
  • Synthesis of current knowledge on EP receptor functions in health and disease.

Main Results:

  • COX-2 and PGE2 are significantly associated with cancer development and progression.
  • Inhibition of PGE2 synthesis has demonstrated therapeutic potential but is hampered by toxicities.
  • Understanding individual EP receptor functions is crucial for developing targeted therapies.

Conclusions:

  • E-type prostanoid receptors represent promising therapeutic targets for cancer treatment.
  • Targeting specific EP receptors may offer a safer alternative to broad COX-2 inhibition.
  • Further research into EP receptor signaling pathways can lead to novel anti-cancer strategies.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

10.0K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
609
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K